AnaptysBio, Inc.

ANAB

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Jan 15, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
Rosnilimab	Phase 2	Rheumatoid Arthritis	-
Etokimab	Phase 2	Chronic Rhinosinusitis	-
Placebo	Phase 2	Atopic Dermatitis	-

Catalyst Timeline

2 upcoming, 0 past

Phase 2Next

January 2026~Placebo

Primary completion for Placebo trial (NCT06127043) in Ulcerative Colitis

Phase 2

January 2026~Rosnilimab

Primary completion for Rosnilimab trial (NCT06127043) in Ulcerative Colitis

Regulatory Approvals

ANAB News